Vendor Intelligence Report: Deuschem

Published 3 Jul 2026. 31-page investigative report on who is behind Deuschem: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 29 Finnrick lab tests, Deuschem's overall pass rate is 24%: 7 pass and 22 fail. The record is uneven: Melanotan II is the clearest defensible pocket and Semaglutide is the next-best GLP-1 read, while CJC-1295 and Ipamorelin sit in repeated-failure territory. The full report shows why public ratings can look less severe than the pass/fail count when stricter grading is applied.

The investigation also separates authenticity from recourse. Deus Medical's own verification surface still confirms deuschem.com as an authorized reseller, a real positive against copycats. But the captured Terms and Privacy Policy disclose no legal entity, VAT number or physical address, and the supply-chain trail runs through a West Bengal private company with small paid-up capital and director turnover.

The infrastructure picture changed in 2026: an official Reddit account directed buyers toward deuschem.to while upstream verification still centered the .com domain. Certificate-transparency records confirm the alternate domain is active; the report treats the migration as a high-severity buyer-authentication event, not proof of motive. Trustpilot removal, a 0/100 ScamAdviser score and fake-site warnings add surface risk.

Operationally, the recent complaint pattern is specific: tracking labels generated, no visible courier handoff, courier or warehouse explanations, and refund friction. External steroid/AAS reports in the same Deus Medical / Astera ecosystem describe wrong-compound or wrong-ester findings. Retatrutide appears in the catalog without a supplied Deuschem Finnrick test line and carries separate GLP-1 concentration-risk warnings.

Inside the full report:

  • Appendix A with per-product Finnrick pass/fail data, rating trajectories and methodology-divergence charts for all 7 tested peptides
  • Corporate-identity and recourse analysis covering storefront disclosures, seller verification, manufacturer attribution, paid-up capital and director turnover
  • Domain and channel analysis of deuschem.com, active deuschem.to certificates, Reddit migration posts and Telegram handles
  • Delivery-risk evidence from Reddit, Eroids and forums, including the stalled-tracking pattern and US shipping suspension
  • External product-integrity review of Madsen Akademie / Janoshik-linked reports and Astera Labs complaints

Risk assessment

  • Peptide quality failures in Finnrick testing — high: Finnrick tested 29 Deuschem peptide samples with 7 pass / 22 fail; fail-heavy products include Ipamorelin, BPC-157, CJC-1295, PT-141 and Tirzepatide, while Melanotan II and Semaglutide perform better.
  • Wrong-compound and mislabeled-product risk outside the peptide panel — high: External records report Masteron / Primobolan / Testomed label mismatches in Deus Medical and Astera lines; these are non-peptide AAS reports, not Finnrick peptide tests.
  • Non-delivery and phantom-tracking risk — high: Reddit, Eroids and forum surfaces describe labels generated without courier handoff, long stalls, repeated courier excuses and unresolved orders; US shipping has been suspended since August 2025.
  • Domain migration and brand-confusion risk — high: Official Reddit activity directs users to active deuschem.to while Deus Medical verification still centers deuschem.com; fake-site warnings exist and storefront anti-counterfeit controls are limited.
  • Retatrutide-specific regulatory and concentration risk — high: Deuschem markets Retatrutide 10mg; regulators have warned about unapproved GLP-1 peptides and illicit Retatrutide concentration errors, and no Deuschem-specific Retatrutide Finnrick test line is supplied.
  • Legal-identity and corporate-recourse opacity — medium: Deuschem’s Terms and Privacy Policy disclose no legal entity, VAT number or physical address; manufacturer attribution traces to EZCORE in India with small paid-up capital and director turnover.
  • Review-platform enforcement and external warning risk — medium: Trustpilot removed the Deuschem profile for guideline reasons and ScamAdviser shows a 0/100 score; these are secondary signals but corroborate broader identity and conduct concerns.
  • Affiliate-promotion risk — medium: Deuschem runs a 10% affiliate program and the scan found referral-code or coupon promotion without clear disclosure from @pr0dota, u/no_ebb_6831 and SpendMoneySmart surfaces.